Prophylaxe und Therapie venöser Thromboembolien bei Tumorpatienten

Schlüsselwörter

tiefe Venenthrombose - Lungenarterienembolie - Tumorerkrankung - Antikoagulation

Keywords

deep vein thrombosis - pulmonary embolism - malignant disease - anticoagulation

• Literatur

• 1 Agnelli G, George DJ, Kakkar AK et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601-609
• 2 Agnelli G, Gussoni G, Bianchini C et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 943-949
• 3 Ay C, Dunkler D, Marosi C et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377-5382
• 4 The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510
• 5 Guyatt GH, Akl EA, Crowther M et al. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (Suppl. 02) (Suppl.) 7S-47S
• 6 Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815
• 7 Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907
• 8 Lee AY, Levine MN, Baker RI. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153
• 9 Levine MN, Deitchmann D, Julian J et al. A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer. J Clin Oncol 2009; 27 (Suppl. 01) Abstract e20514
• 10 Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology Guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505
• 11 Mandalà M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl. 06) vi85-vi92
• 12 Maraveyas A, Waters J, Roy R et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48: 1283-1292
• 13 Pabinger I, Alt-Epping B, Demarmels Biasutti F et al. Venöse Thromboembolien bei Tumorpatienten. Onkopedia-Leitlinie in Kooperation mit der Gesellschaft für Thrombose- und Hämostaseforschung e.V. und der Deutschen Gesellschaft für Palliativmedizin. Hämostaseologie 2011; 31: 281-290
• 14 Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488
• 15 Riess H, Pelzer U, Opitz B et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial. J Clin Oncol 2010; 28 (Suppl. 01) Abstract 4033
• 16 Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352
• 17 Sorensen HT, Mellemkjaer L, Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850